Platform Technologies

Two Platforms.
A Portfolio of Possibility.

Versatile delivery technologies engineered to generate multiple therapeutic and diagnostic products from a shared scientific foundation—maximizing intellectual property value while reducing single-product risk.

Exosome Platform

Natural extracellular vesicles, engineered for targeted therapeutic delivery.

Precision-engineered exosomes designed to carry therapeutic cargo directly to their intended target, harnessing the natural biology of extracellular vesicles.

  • RNA therapeutics
  • Protein therapeutics
  • Regenerative medicine
  • Immunotherapy
  • Precision medicine
Nanolipid Platform

Next-generation lipid nanoparticles for delivery and advanced imaging.

Next-generation lipid nanoparticle technologies optimized for therapeutic delivery and advanced molecular imaging.

  • Oncology
  • Contrast imaging
  • Theranostics
  • Precision drug delivery

Large Addressable Markets

Delivery technologies applicable across major therapeutic and diagnostic categories.

  • Oncology
  • Autoimmune disease
  • Regenerative medicine
  • RNA therapeutics
  • Molecular imaging
  • Cell & gene therapy

Platform IP Strategy

BioBridge is actively expanding its intellectual property portfolio through internal innovation, strategic licensing, and collaborative development to build a diversified portfolio of high-value biotechnology assets.

Pipeline

Our Program Pipeline

Multiple pipeline opportunities can be developed from shared platform technologies—allowing each scientific advance to generate multiple commercial applications across therapeutics, imaging, and regenerative medicine.

BioBridge Health program pipeline: Nanolipid Imaging Platform (Licensing & Development), Exosome Drug Delivery Platform (Preclinical), Regenerative Medicine Products (Development), and Next Generation Delivery Systems (Discovery).
Innovative platforms. Transformative potential. Programs span discovery through licensing and development.
Partner With Us

Advance a Program Together

We collaborate with academic institutions, pharmaceutical companies, CDMOs, and research organizations to accelerate development across our platforms.

Start a Conversation